Shidlovski Shares of Rezolute ( NASDAQ: RZLT ) shot up 50% in post-market trading Tuesday after it reported that a Phase 2 proof-of-concept study for its orally administered drug RZ402 met its primary endpoints in the treatment of diabetic macular edema. Rezolute said the endpoints were safety and reduction in central subfield thickness. The drug was tested on patients with the eye condition who were either treatment naïve or had received limited anti-VEGF injections, according to a statement .

The company said the product, which is non-invasive, could allow for earlier treatment of the disease, which can cause blindness. More on Rezolute Seeking Alpha’s Quant Rating on Rezolute Historical earnings data for Rezolute Financial information for Rezolute.